Lisa Cosgrove

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8665760/publications.pdf

Version: 2024-02-01

57	1,525	20	36
papers	citations	h-index	g-index
58	58	58	1177 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry. Psychotherapy and Psychosomatics, 2006, 75, 154-160.	8.8	196
2	A Comparison of DSM-IV and DSM-5 Panel Members' Financial Associations with Industry: A Pernicious Problem Persists. PLoS Medicine, 2012, 9, e1001190.	8.4	150
3	Psychiatry Under the Influence. , 2015, , .		126
4	Conflicts of Interest and Disclosure in the American Psychiatric Association's Clinical Practice Guidelines. Psychotherapy and Psychosomatics, 2009, 78, 228-232.	8.8	116
5	Conflicts of interest and the quality of recommendations in clinical guidelines. Journal of Evaluation in Clinical Practice, 2013, 19, 674-681.	1.8	78
6	Marginalized Mothers: Parenting Without a Home. Analyses of Social Issues and Public Policy, 2005, 5, 127-143.	1.7	70
7	Speaking for Ourselves: Feminist Methods and Community Psychology. American Journal of Community Psychology, 2000, 28, 815-838.	2.5	62
8	The poison in the cure: Neoliberalism and contemporary movements in mental health. Theory and Psychology, 2018, 28, 669-683.	1.2	45
9	Constructions of Femininity and Experiences of Menstrual Distress. Women and Health, 2003, 38, 37-58.	1.0	44
10	Antidepressants and Breast and Ovarian Cancer Risk: A Review of the Literature and Researchers' Financial Associations with Industry. PLoS ONE, 2011, 6, e18210.	2.5	44
11	Crying Out Loud: Understanding Women's Emotional Distress as both Lived Experience and Social Construction. Feminism and Psychology, 2000, 10, 247-267.	1.8	40
12	Tripartite Conflicts of Interest and High Stakes Patent Extensions in the DSM-5. Psychotherapy and Psychosomatics, 2014, 83, 106-113.	8.8	39
13	Industry's colonization of psychiatry: Ethical and practical implications of financial conflicts of interest in the DSM-5. Feminism and Psychology, 2013, 23, 93-106.	1.8	38
14	Consistency and sources of divergence in recommendations on screening with questionnaires for presently experienced health problems or symptoms: a comparison of recommendations from the Canadian Task Force on Preventive Health Care, UK National Screening Committee, and US Preventive Services Task Force. BMC Medicine, 2017, 15, 150.	5.5	37
15	A critical review of the Lancet Commission on global mental health and sustainable development: Time for a paradigm change. Critical Public Health, 2020, 30, 624-631.	2.4	33
16	Reporting of financial conflicts of interest by Canadian clinical practice guideline producers: a descriptive study. Cmaj, 2020, 192, E617-E625.	2.0	28
17	Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media. BMJ Evidence-Based Medicine, 2019, 24, 231-238.	3.5	27
18	Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation. Accountability in Research, 2016, 23, 257-279.	2.4	25

#	Article	IF	CITATIONS
19	Developing a Clinician Friendly Tool to Identify Useful Clinical Practice Guidelines: G-TRUST. Annals of Family Medicine, 2017, 15, 413-418.	1.9	24
20	The Aftermath of Pregnancy Loss. Women and Therapy, 2004, 27, 107-122.	1.0	22
21	The Need to Systematically Evaluate Clinical Practice Guidelines. Journal of the American Board of Family Medicine, 2016, 29, 644-648.	1.5	22
22	Forgiveness and Forgetting: Clinical Implications for Mental Health Counselors. Journal of Mental Health Counseling, 2008, 30, 1-13.	0.9	22
23	Antipsychotic augmentation for major depressive disorder: A review of clinical practice guidelines. International Journal of Law and Psychiatry, 2017, 55, 64-71.	0.9	21
24	When is a guideline not a guideline? The devil is in the details. BMJ Evidence-Based Medicine, 2018, 23, 33-36.	3.5	20
25	From <i>caveat emptor</i> to <i>caveat venditor</i> : time to stop the influence of money on practice guideline development. Journal of Evaluation in Clinical Practice, 2014, 20, 809-812.	1.8	19
26	Conflict of Interest Policies and Industry Relationships of Guideline Development Group Members: A Cross-Sectional Study of Clinical Practice Guidelines for Depression. Accountability in Research, 2017, 24, 99-115.	2.4	19
27	Conflicts of Interest and the Presence of Methodologists on Guideline Development Panels: A Cross-Sectional Study of Clinical Practice Guidelines for Major Depressive Disorder. Psychotherapy and Psychosomatics, 2017, 86, 168-170.	8.8	19
28	Ten years later: a review of the US 2009 institute of medicine report on conflicts of interest and solutions for further reform. BMJ Evidence-Based Medicine, 2022, 27, 46-54.	3.5	16
29	Feminism, Postmodernism, and Psychological Research. Hypatia, 2003, 18, 85-112.	0.6	15
30	Reconceptualising treatment-resistant depression as difficult-to-treat depression. Lancet Psychiatry,the, 2021, 8, 11-13.	7.4	12
31	Unexamined assumptions and unintended consequences of routine screening for depression. Journal of Psychosomatic Research, 2018, 109, 9-11.	2.6	10
32	Resisting Essentialism in Feminist Therapy Theory. Women and Therapy, 2002, 25, 89-112.	1.0	9
33	The Cultural Politics of Mental Illness: Toward a Rights-Based Approach to Global Mental Health. Community Mental Health Journal, 2021, 57, 3-9.	2.0	9
34	Global mental health. Lancet, The, 2019, 394, 117-118.	13.7	8
35	No Magic Pill: A Prescription for Enhanced Shared Decision-Making for Depression Treatment. Journal of the American Board of Family Medicine, 2019, 32, 6-9.	1.5	7
36	Beware of equating increased access to mental health services with health equity: The need for clinical and epistemic humility in psychology Humanistic Psychologist, 2021, 49, 338-341.	0.3	6

#	Article	IF	CITATIONS
37	Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and Therapeutics Bulletin, 2021, 59, 185-188.	0.3	6
38	Digital Phenotyping and Digital Psychotropic Drugs: Mental Health Surveillance Tools That Threaten Human Rights. Health and Human Rights, 2020, 22, 33-39.	1.3	6
39	Strengthening conflictâ€ofâ€interest policies in medicine. Journal of Evaluation in Clinical Practice, 2010, 16, 21-24.	1.8	5
40	Institutional corruption in psychiatry: Case analyses and solutions for reform. Social and Personality Psychology Compass, 2018, 12, e12394.	3.7	5
41	Global health, human rights, and neoliberalism: The need for structural frameworks when addressing mental health disparities Journal of Theoretical and Philosophical Psychology, 2022, 42, 52-60.	0.9	4
42	What is Postmodernism and How is it Relevant to Engaged Pedagogy?. Teaching of Psychology, 2004, 31, 171-177.	1,2	3
43	Depression Screening During Pregnancy and the Postpartum Period: Enhancing Informed Consent Practices. Women's Reproductive Health, 2018, 5, 1-12.	0.8	3
44	Why a rights-based approach is not anti-psychiatry. Australian and New Zealand Journal of Psychiatry, 2019, 53, 503-504.	2.3	3
45	Drivers of and Solutions for the Overuse of Antidepressant Medication in Pediatric Populations. Frontiers in Psychiatry, 2020, 11, 17.	2.6	3
46	Conflicts of Interest in Psychopharmacology Textbooks. Community Mental Health Journal, 2021, , 1.	2.0	3
47	Corruption impairs discussion on long term use of psychiatric drugs. BMJ, The, 2015, 350, h2953-h2953.	6.0	2
48	The Influence of Pharmaceutical Companies and Restoring Integrity to Psychiatric Research and Practice., 2019,,71-96.		2
49	Evidence-based practice: a comparison of International Clinical Practice Guidelines and current research on physical activity for mild to moderate depression. Translational Behavioral Medicine, 2019, 9, 703-710.	2.4	1
50	Institutional corruption in psychiatric research and practice: Implications for humanistic psychology Humanistic Psychologist, 2023, 51, 56-70.	0.3	1
51	Variation in analytic transparency in recent efficacy studies of antidepressant medication. BMJ Evidence-Based Medicine, 2018, 23, 177-182.	3.5	0
52	Digital aripiprazole as a human technology. Economy and Society, 2021, 50, 359-373.	2.4	0
53	The End Product: Clinical Practice Guidelines. , 2015, , 135-151.		0
54	Economies of Influence. , 2015, , 27-41.		O

LISA COSGROVE

#	Article	IF	CITATIONS
55	Feminism, Postmodernism, and Psychological Research. Hypatia, 2003, 18, 85-112.	0.6	0
56	Mental Health as a Basic Human Right and the Interference of Commercialized Science. Health and Human Rights, 2020, 22, 61-68.	1.3	0
57	Industry effects on evidence: a case study of long-acting injectable antipsychotics. Accountability in Research, 2024, 31, 2-13.	2.4	O